Back to News
Market Impact: 0.2
GSK Announces Positive Phase Ib Data for Mo-Rez with 62% Response Rate
Source: Nasdaq
Healthcare & Biotech
GSK announced updated data from the global Phase I BEHOLD-1 trial of mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate. The article text is truncated before the reported results are specified, so efficacy, safety, and any market reaction cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GSK0.40
More News
- Hansoh and GSK drug extends survival in bone cancer study
- GSK cancer drug clears rectal tumours in 76% of patients in trial, data shows
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma